Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Table 4 Treatment-related adverse events (≥ 5%) in patients after propensity score matching, n (%)

	Patients with OBBT (n = 32)		Patients without OBBT (n = 61)
	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Any TRAEs	32 (100)	13 (40.6)	55 (90.2)	23 (37.7)
Leukopenia/Neutropenia	23 (71.9)	5 (15.6)	39 (64.0)	13 (21.3)
Constipation	18 (56.3)	0	33 (54.1)	0
Peripheral sensory neuropathy	17 (53.1)	1 (3.1)	30 (49.2)	3 (4.9)
Fatigue	16 (50.0)	0	30 (49.2)	0
Decreased appetite	14 (43.8)	1 (3.1)	29 (47.5)	0
Thrombocytopenia	13 (40.6)	6 (18.8)	16 (26.2)	2 (3.3)
Nausea	12 (37.5)	1 (3.1)	27 (44.3)	4 (6.5)
Vomiting	4 (12.5)	2 (6.3)	13 (21.3)	4 (6.5)
Diarrhea	4 (12.5)	2 (6.3)	14 (23.0)	5 (8.2)
Infection	3 (9.4)	0	5 (8.2)	0
Oral mucosal ulcer	2 (6.3)	0	6 (9.8)	2 (3.3)
Febrile neutropenia	1 (3.1)	1 (3.1)	6 (9.8)	6 (9.8)
Liver injury	1 (3.1)	0	4 (6.5)	1 (1.6)

OBBT: Overt bleeding before treatment; TRAEs: Treatment-related adverse events.